Interviews

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses step therapy and its impact on patients.

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses credible, patient-friendly resources that people with rheumatic diseases can access when they or their providers are considering a switch to a biosimilar.

Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses lessons learned from international experience with biosimilar uptake.

Ray Bailey, RPh, Pharmacy Director at Florida Cancer Specialists, discusses the complexities of biosimilars.

Linda Frisk, PharmD, of Arizona Oncology, discusses biosimilars and cost savings.

Julianne Orr, outpatient oncology clinical pharmacist, Indiana University Health, explains that biosimilars remain a gray area for pharmacists.

Steven D’Amato, RPh, executive director and clinical pharmacy specialist at New England Cancer Specialists, explains the factors that he feels will impact adoption of biosimilars.

Howard Cohen, RPh, MS, FASHP, director of oncology pharmacy services for Yale New Haven Hospital, discusses using biosimilar filgrastim.

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, discusses the role that the Federal Trade Commission (FTC) may play in encouraging biosimilar competition.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, explains that his organization welcomes biosimilars to the treatment landscape.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, explains what biosimilar developers should know about patients with rheumatic diseases.

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses guidelines for the treatment of cancer.

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, discusses the differences between patent litigation for biologics and biosimilars under the BPCIA and small-molecule drugs and their generics under the Hatch-Waxman acts.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses trends in state laws that address the eventual substitution of interchangeable biosimilars for reference biologics.

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, discusses whether the FDA might involve itself in answering the lingering questions concerning the Biologics Price Competition and Innovation Act (BPCIA).

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses how payers might address Herceptin after the advent of biosimilar trastuzumab.

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, describes the challenges associated with treating different subtypes of breast cancer.

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, discusses trends in recent congressional discussions about the high cost of prescription drugs.

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, disucusses the conversations she is having and expects to have with fellow prescribers about biosimilars in oncology.

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses the ways in which payers will drive the use of Mylan and Biocon's trastuzumab biosimilar, Ogivri, in patients once it becomes commercially available.

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses advances in the treatment of HER2-positive breast cancer.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses non-medical switching of patients from high-cost reference biologics to biosimilars (or to other therapies).

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, explains some of the challenges with proposals to allow the United States to import cheaper drugs from Canada or other highly regulated pharmaceutical markets.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, addresses the importance of patient assistance programs.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses CMS' proposal to treat biosimilars as generics for the purpose of cost-sharing.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, explains what patients should know about biosimilar therapies.

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, describes trends in state legislation on drug pricing and industry reaction to such laws.

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, describes how the FDA has changed under its current leadership.

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, reflects on physician efforts to educate patients about biosimilars.

Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, responds to Allergan's recent transfer of patents to a soverign entity, and gives 2 takeaways for industry.